On Wednesday, October 23, Jim McCamant, editor of the "Medical Technology Stock Letter," joined Worth OnLine for a live "Conference Call." The "Medical Technology Stock Letter" provides expert analysis of developments and investment opportunities in the area of medical biotechnology. Although the biotechnology "crash" of 1992 has made positive returns hard to come by in recent years, the stocks recommended by McCamant's MTSL rose 108 percent in 1995. Follows is a transcript from the evening's event, edited for clarity. The opinions expressed are those of Jim McCamant, and do not represent those of Worth, Worth OnLine, or Capital Publishing.